The Impact of Surgical Treatment on Survival in Localized Small Cell Esophageal Cancer
Limited-stage small cell esophageal carcinoma (LS-SCEC) is a rare and highly aggressive malignancy with poor prognosis and no established standard treatment strategy. Due to its low incidence, current evidence is mainly derived from small retrospective studies, and the role of surgery in multimodal treatment remains co
| Condition(s) | Esophageal Carcinoma, Limited-Stage Small Cell Esophageal Carcinoma |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | Limited-stage small cell esophageal carcinoma (LS-SCEC) is a rare and highly aggressive malignancy with poor prognosis and no established standard treatment strategy. Due to its low incidence, current evidence is mainly derived from small retrospective studies, and the role of surgery in multimodal treatment remains controversial. In particular, the survival benefit of surgical treatment compared with definitive non-surgical therapy has not been fully clarified. This single-center retrospective cohort study aims to evaluate the impact of surgical versus non-surgical treatment strategies on survival outcomes in patients with LS-SCEC. Patients receiving surgical treatment, including surgery alone, neoadjuvant therapy followed by surgery, or surgery followed by adjuvant therapy, will be compa |
| Who can participate | Inclusion Criteria: * Patients pathologically diagnosed with primary small cell esophageal carcinoma (SCEC). * Patients classified as having limited-stage disease at initial diagnosis, defined as tumor confined to the esophagus and/or regional lymph nodes without evidence of distant metastasis. * Patients who received definitive treatment at the study institution, including surgical treatment (with or without neoadjuvant or adjuvant therapy) or definitive non-surgical treatment such as chemoradiotherapy-based therapy. * Patients with complete baseline clinicopathological and treatment information available in the medical records. * Patients with available follow-up and survival outcome data. Exclusion Criteria: * Patients with extensive-stage disease or distant metastasis at diagnosis. * P |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | yi shen |
| Locations | Nanjing, Jiangsu, China |
| Start date | 2026-05-15 |
| NCT ID | NCT07596654 |
| Official listing | https://clinicaltrials.gov/study/NCT07596654 |